Effects of a novel Hungarian antacid containing Al and Mg (Tisacid) on mucosal prostaglandin generation and oxygen free radicals in normal rats.
A new patented chemical agent (Al-Mg-hydroxy-carbonate; acid-binding capacity greater than 30 mmol/g) was produced by our work-team. After our preliminary pharmacological and some prospective, randomized, multicentre, controlled clinical studies, this antacid was registered (Tisacid tablet and suspension; Alkaloida, Hungary). A cumulative ulcer healing rate of 80-85% was proved by Tisacid monotherapy applied in low doses (from 80 to 160 mmol/day) in patients with duodenal ulcer. The aims of this study were: (i) to determine the role of different antacids on the genesis of mucosal prostaglandins (PGs) (PGE2 and 6-keto-PGF1 alpha) in normal rats; (ii) to evaluate the effects of indomethacin pre-treatment (20 mg/kg b.w.,s.c.) on the Tisacid-induced alterations of gastric mucosal PG-contents; (iii) to analyse the generation of oxygen free radicals and lipid peroxidation in the rat oxyntic mucosa by the application of different doses of Tisacid (activities of CAT, GSH-px and SOD, contents of MDA and red. GSH). It was found that: Tisacid has a potent gastroproprotective effect in gastric mucosa, via (a) an increase in the mucosal levels of PGs, and (b) a scavenging-like effect in normal rat gastric mucosa. It is concluded that the gastroprotective effect of Tisacid appears because of the following: (i) excellent acid-neutralizing capacity; (ii) mucosal generation of PGs (PGE2 and PGI2); (iii) free radical scavenging; (iv) its possible activity as a Ca-antagonist (Mg-containing compound).
Nagy
L
L
First Department of Medicine, University Medical School, Pécs, Hungary.
Mózsik
G
G
Vincze
A
A
Süto G
Hunyady
B
B
Rinfel
J
J
Past
T
T
Jávor
T
T
D015121:6-Ketoprostaglandin F1 alpha / Q000096:biosynthesis; D000536:Aluminum Hydroxide / Q000494:pharmacology*; D000818:Animals; D000863:Antacids / Q000494:pharmacology*; D002254:Carbonates / Q000494:pharmacology*; D015232:Dinoprostone / Q000096:biosynthesis; D004305:Dose-Response Relationship, Drug; D005260:Female; D005609:Free Radicals; D005753:Gastric Mucosa / Q000033:anatomy & histology / Q000187:drug effects / Q000378:metabolism*; D005978:Glutathione / Q000378:metabolism; D007213:Indomethacin / Q000494:pharmacology; D015227:Lipid Peroxidation; D008276:Magnesium Hydroxide / Q000494:pharmacology*; D008297:Male; D008315:Malondialdehyde / Q000378:metabolism; D010100:Oxygen / Q000378:metabolism*; D011453:Prostaglandins / Q000096:biosynthesis*; D051381:Rats; D011919:Rats, Inbred Strains; D013997:Time Factors
D000863:Antacids; D002254:Carbonates; D005609:Free Radicals; D011453:Prostaglandins; D008315:Malondialdehyde; C043698:almagate; D015121:6-Ketoprostaglandin F1 alpha; D000536:Aluminum Hydroxide; D005978:Glutathione; D015232:Dinoprostone; D008276:Magnesium Hydroxide; D010100:Oxygen; D007213:Indomethacin